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Abstract
Background: Human papilloma virus (HPV) in patients with esophageal carcinoma has previously
been studied with an average detection rate of 15%, but the role of HPV in relation to survival is
less clear. In cervical cancer, lung cancer and tonsil cancer HPV viral load is a predictive factor for
survival and outcome of treatment. The primary aim was to study the spectrum of high-risk HPV
types in esophageal tumors. Secondary, as a pilot study we investigated the association between
HPV status and the survival rates.
Methods: We compared both the presence and the viral load of high-risk HPV types 16, 18, 31,
33, 39, 45, 52, 58, and 67 in relation to clinical data from patients with esophageal carcinoma.
Survival data and tumor samples were retrieved from 100 patients receiving treatment at the
Department of Oncology, Uppsala Hospital, Uppsala, Sweden. The tumor samples were
investigated for HPV viral load using real-time PCR.
Results: HPV 16 was detected in 16% of the patients; no other HPV type was detected. HPV 16
infection had no significant effect on survival (p = 0.72). Also, HPV 16 did not improve survival after
treatment (radiotherapy or chemotherapy).
Conclusion: Only HPV 16 was detected among the patients. HPV 16 in esophageal carcinoma
patients did not influence survival or improve therapy response. However, given the size of the
study there is a need to examine a larger cohort in order to understand in more detail the effect
of high risk HPV types in esophageal carcinoma.
Background
High-risk HPV type infections is detected with polymerase
chain reaction (PCR) in approximately 15% of esophageal
carcinoma patients [1]. The incidence of high-risk HPV
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type in esophageal carcinoma varies between different
geographical areas [1]. It is postulated that areas with high
incidence of esophageal carcinoma have higher rates of
HPV than in areas with low incidence of esophageal carci-
noma [2]. According to epidemiological studies, HPV 16
is the most prevalent HPV type in cervical cancer, followed
by HPV 18, 45, 31, and 33, in descending order [3]. HPV
infections of squamous cells can induce hyperplasia and
papilloma [4] and in vitro studies have further revealed
that the exposing of human fetal esophageal cells to HPV-
18 results in immortalization and development of human
esophageal carcinoma cells [5].
In patients with tonsil cancer, the presence of HPV in the
tumors correlates with better survival [6]. In a study of
patients with cervical carcinoma receiving radiation ther-
apy, HPV-positive patients have a significantly better sur-
vival rate [7]. However, within in vitro studies the
chemosensitivity as well as radiation sensitivity is
decreased in HPV-infected cells [8,9]. The immune
response might affect survival, but this seems to depend
on the whether HPV is present in episomal form or as
integrated virus. In patients with cervical carcinomas,
higher quantities of antibodies against HPV-16 is seen
with episomal HPV as compared to integrated HPV DNA
[10]. The mechanisms used by high-risk HPV genotypes
(HPV 16, 18, 31, 33, 39, 45, 52, 58 and 67) to overcome
the normal cell cycle control is mediated by the HPV viral
oncoproteins E6 and E7, which cause inactivation of the
tumor suppressor genes p53 and Rb [11].
In the present study, viral load in a series of high-risk HPV
types (16, 18, 31, 33, 39, 45, 52, 58 and 67) were deter-
mined in esophageal carcinoma tumors. Secondary, as a
pilot study we investigated the association between HPV
status and survival in patients with esophageal carcinoma.
Methods
Ethics
The study was reviewed and approved by the research eth-
ics committee, Uppsala University, Uppsala, Sweden.
Patients characteristics
Patients with esophageal carcinoma, admitted to the
Department of Oncology, University Hospital, Uppsala,
Sweden, during 1990–2000 were identified. These
patients formed a consecutive series. A total of 126
patients fulfilled the inclusion criteria but 26 patients
were lost due to inadequate (n = 9) or absence of histolog-
ical material (n = 17). The present study is based on a ret-
rospective examination of esophageal carcinoma
diagnostic biopsy samples from clinical cases, all retrieved
tumor samples were re-evaluated before analysis.
The following parameters were studied: age, gender,
weight loss, performance status according to the Eastern
Cooperative Oncology Group (ECOG) [12] at first admit-
tance, smoking habits, alcohol habits and differentiation
of the tumor. Anatomical localization of the tumor were
grouped into an upper part (15–24 cm), a middle part
(25–34 cm) and a lower part of the esophagus (35–46 cm.
The tumor status were characterized into localized (Pri-
mary tumor with or without local node metastases) or
advanced disease (With distant metastases).
Treatment strategy was recorded as:
1. Preoperative radiation treatment, total dose of 40 Gy in
2 Gy fractions. This irradiation was given concomitant
with chemotherapy (Cisplatin 100 mg/m2 and 5-FU 750
mg/m2, three cycles with an interval of three weeks of
which two were given concomitantly).
2. Curatively intended radiation treatment, total doses
60–64 Gy.
3. Palliative treatment included radiation treatment, total
dose 36 Gy in 3 Gy fractions. These patients also received
brachytherapy and in some cases, also palliative chemo-
therapy.
4. Palliative treatment only including chemotherapy.
HPV plasmids
Plasmids containing HPV 16, 18, 31, 33, 39, 45, 52, 58
and 67 were supplied by T. Matsukura (National Institute
of Health, Japan), A. Lörincz (Digene Corporation) or G.
Orth (Institut Pasteur, Paris) or prepared by cloning from
PCR products of clinical samples. The plasmids were used
both as positive controls and to estimate the sensitivity of
the assay.
Deparaffination procedure
The biopsies were fixated by treatment in buffered forma-
lin followed by paraffin embedding. Paraffin blocks from
the primary tumor were cut in 10-µm sections and 4 sec-
tions/patient were collected in the same microcentrifuge
tube. Samples were de-waxed in 1 ml xylene for 5 min. in
room temperature and centrifuged at 14,000 rpm for 5
min. The supernatant was removed. This step was then
repeated 5 times. Samples were gently vortexed between
each step. 1 ml 95% ethanol was then added for 5 min. in
room temperature and this was repeated with 70% etha-
nol. The samples were centrifuged 14.000 rpm for 5 min.
between the ethanol changes. The samples were then
dried in a 37°C heated block with open lids for 20 min.
to remove residual ethanol.BMC Cancer 2006, 6:94 http://www.biomedcentral.com/1471-2407/6/94
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Table 1: Demographic description of patients for all investigated parameters. The distribution of HPV 16 positivity and median viral 
load is shown for all clinical subgroups. Tumor stage and performance status according to ECOG were correlated to patients survival 
in the univariate survival analysis, p-value is shown for all parameters. *Treatment management not included in survival analysis.
Number of patients Median survival 
in days
Univariate survival 
analysis p-value for 
each parameter
HPV 16 pos HPV 16 viral load 
median value based on 
positive samples 
(genomes/human 
genome equivalents)
Gender 0.55
Male 71 292 10 2.7
Female 29 338 6 10.5
Age 0.84
65 39 292 7 2.1
65 + 61 307 9 6.6
Tumour stage 0.00055
Advanced disease 30 212 5 2.12
Localised disease 70 376 11 5.3
Histology 0.39
Squamous cell carcinoma 71 250 10 16.4
Adenocarcinoma 27 374 5 0.6
Mucoepidermoid 2 528 1 5.3
Tumor differentiation 0.46
Low differentiated 29 362 4 1.4
Middle 23 234 4 1.9
High 2 187 0 -
Not determined 46
Localisation of tumor 0.17
Upper 11 292 3 15.7
Middle 33 338 6 16.9
Lower 47 235 3 0.16
Not determined 9
Performance status <0.0001
04 3 4 1 9 6 2 . 7
14 3 2 3 5 4 1 6 . 3
28 1 2 0 2 6 0 . 6
34 4 9 3 0 . 6
Not determined 2
Weight 0.12
Weight loss 82 236 10 0.6
No weight loss 18 414 6 6.0
Smoking habits 0.45
Non smoker 16 309 1 5.3
Smoker 45 292 4 8.7
Ex-smokers 22 235 6 2.7
Not determined 17
Alcohol usage 0.81
Alcohol use 50 339 6 5
No alcoholic use 6 450 1 5
Not determined 44
Treatment *
Surgery+ Chemo-
radiation
13 493 1 0.5
Curativ intended Chemo-
radiation
24 445 5 5,3
Palliative chemotherapy 
and radiotherapy
47 234 5 15,7
Palliative chemotherapy 16 125 5 0.6BMC Cancer 2006, 6:94 http://www.biomedcentral.com/1471-2407/6/94
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Proteinase K digestion
200–400 µl of dilution buffer was added to each tube (0.2
M Tris-HCL pH 8.0, 1% sodium dodecyl sulfate, 10 mM
EDTA, 1 mg/ml proteinase K). The volume of the dilution
buffer was dependent of the amount of tissue available.
Samples were subsequently incubated at 50°C overnight
and thereafter heated to 94°C for 10 min. to inactivate the
proteinase K.
Protein precipitation
50 µl of saturated NaCl solution (approximately 6 M) was
added to each tube and the samples gently vortexed for 5
min. The tubes were then centrifuged at 14.000 rpm at
room temperature for 5 min. After centrifugation, white
pellets were visible in the bottom of the tubes and super-
natants were transferred to a new tube.
DNA precipitation
DNA was precipitated with 2.5 volumes of 95% ethanol
in -20°C for 1 hour and then pelleted by centrifugation at
14.000 rpm in room temperature for 30 min. The pellet
was then washed with 70% ethanol followed by centrifu-
gation for 5 min. DNA pellets were air dried and finally re-
suspended in 100 µl TE buffer (100 mM Tris-HCL, pH8.0,
1 mM EDTA).
Real-time PCR
The detection of the HPV was performed using a real-time
PCR based method previously described [13]. Briefly, the
real-time PCR assay detects and quantifies HPV 16, 18, 31,
33, 39, 45, 52, 58 and 67. The assay is based on three par-
allel real-time PCRs from each patient sample: a) Reaction
1 detects and quantifies HPV types 16, 31, 18 and 45
(HPV 18 and 45 detected and quantified together) using
three different fluorophores, b) Reaction 2 detects and
quantifies HPV types 33, 39, 52, 58 and 67 (HPV 33, 52,
58 and 67 detected and quantified together), again using
three different fluorophores, and c) Reaction 3 detects and
quantifies the amount of a human single copy gene
(HMBS, Homo sapiens hydroxymethylbilane synthase,
GenBank accession number M95623.1). Reaction 1
includes a total of seven PCR primers and three probes,
Reaction 2 a total of five PCR primers and two probes and
Reaction 3, two PCR primers and a single probe. All probe
and primer sequences have been described [13]. By relat-
ing the HPV copy number to the number of nuclear gene
equivalents (from Reaction 3) a measure of HPV load is
obtained.
The system has a dynamic range from 102 to 107 HPV cop-
ies per assay and is applicable to both fresh clinical sam-
ples and DNA extracted from archival samples.
Reconstitution experiments, made to mimic infections
with several HPV types, shows that individual HPV types
can be detected in a mixture as long as they represent 1–
10 percent of the main type. The system has been evalu-
ated with respect to technical specificity and sensitivity,
reproducibility, reagents stability, sample preparation
protocol and applied to the analysis of clinical samples.
This homogeneous assay provides a fast and sensitive way
for estimating the viral load of a series of the most fre-
quent oncogenic HPV types in biopsies.
The PCR amplification was performed in a 25 µl volume
containing 1× PCR buffer gold (Applied Biosystems, Fos-
ter City, CA, USA), 300 µM 6-carboxy-X-rodamine
(Molecular Probes inc, Eugene OR, USA), 3.5 mM MgCl2,
200 nM each of dATP, dCTP, dGTP and 400 nM dUTP
(Pharmacia Biotech, Uppsala, Sweden), 0.625 U Ampli-
Taq Gold (Applied Biosystems, Foster City, CA, USA), 3 µg
BSA (Sigma Chemical Co., St. Louis, MO, USA) and 200
nM of each primer and probe, and 3 µl DNA extract.
Amplification and detection was performed using a 7700
Sequence Detection System (Applied Biosystems Inc., Fos-
ter City, CA, USA). The amplification ramp included an
initial hold step of 10 min. at 95°C followed by a two-step
cycle consisting of 15 sec. at 95°C and 1 min. at 57°C,
repeated 40 times. Each real-time PCR run included reac-
tions with no template controls containing all PCR com-
ponents but without template DNA to ensure that the
reagents mix were free of contaminants.
Statistics
The survival rates were estimated with the Kaplan-Meier
product limit method, whereas univariate analysis was
performed with log-rank test. Cox regression analysis was
performed to investigate if certain continuous factors had
a significant effect on survival. Spearman's rank order cor-
relation was utilized for tests of associations between fac-
Survival analysis including all patients based on detection of  amplified HPV 16 DNA in the tumor samples Figure 1
Survival analysis including all patients based on detection of 
amplified HPV 16 DNA in the tumor samples.
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tors. A 5% significance level was used throughout the
study.
Results
A total of 100 patients with esophageal carcinoma were
investigated for the presence of the following types of
human papilloma virus 16, 18, 31, 33, 39, 45, 52, 58, and
67. The patients were followed until 2003 with a median
follow up time of 297 days (5–3675 days) and 11 (11%)
patients were alive after follow-up. Patient's characteristic,
median survival and median viral load for each investi-
gated parameter are listed in Table 1. Univariate analysis
revealed that tumor stage (p = 0.00071) and performance
status according to ECOG (p < 0.0001) were associated
with survival. HPV positive patients characteristics are
listed in Table 2 including viral load, gender, performance
status, stage of disease (localized or with metastases),
treatment approach and survival time.
Prior to the analysis of clinical samples, standard curves
for the different HPV types were generated based on dilu-
tion series of the HPV plasmids, as described [13]. Each
run of samples included negative controls (no PCR tem-
plate) and positive controls (HPV plasmid in low copy
number). In none of the real-time runs did the controls
yield a different signal than that expected. Reaction 3
(containing the reagents for the nuclear single copy gene
HMBS) was used to evaluate the DNA quality. Only sam-
ples with positive reaction was further investigated for
HPV type. The HMBS assay was positive, i.e. the reactions
contained DNA suitable for PCR, in all tumors examined.
Amplification of HPV 16 DNA was detected in 16% of the
patients and no other HPV type was detected. HPV 16 sta-
tus did not influence survival rate (p = 0.72) (Figure 1).
The HPV 16 viral load varied between samples with a
median HPV 16 viral load of 4.3 genomes/human
genome equivalents, but no correlation with survival rate
was detected (p = 0.44) (Figure 2). Histological subgroups
did not have a difference in survival depending on HPV 16
status, either in patients with squamous cell carcinoma (p
= 0.61) or adenocarcinoma (p = 0.49). Finally, HPV 16
status did not have any effect on survival after radiation
treatment (p = 0.16) or chemotherapy (p = 0.22).
Discussion
HPV is an important risk factor for development of cervi-
cal cancer as well as head/neck and anal cancer [14-17]. In
the present study we investigated the presence and viral
load of a series of high-risk HPV genotypes in 100 patients
with esophageal carcinoma using real-time PCR. Tonsil
cancer as well as tumors located in the oropharynx and
hypopharynx have high rates of HPV positive cases. In
tonsil and oropharyngeal tumors approximately half of all
cases harbor detectable HPV, whereas in tumors in the
oral cavity and hypopharynx HPV is detected in approxi-
mately 20% of all cases. According to earlier studies, HPV
16 is the most common type of HPV associated with head
and neck malignancies, while other high-risk HPV types
are rare [13,14]. Smoking and excessive alcohol consump-
tion is considered risk factors for both squamous cell car-
Table 2: Description of HPV positive patients characteristics including viral load, gender, histology, performance status, stage of 
disease, survival days and treatment strategy. *genomes/human genome equivalents. **alive at follow up, censored in the survival 
analyze. Nd-the parameter could not be determined. Histology: ESCC-Squamous cell carcinoma, AC-Adenocarcinoma, MEC-
Mucoepidermoid carcinoma. Treatment strategy: 1. Pre-operative concommitant chemoradiotherapy, 2. Curatively intended 
radiotherapy 2–60 Gy, 3. Palliative intended radiotherapy and chemotherapy, 4. Palliative care including chemotherapy.
HPV16 Viral 
load*
Gender Histology Performace 
status
Advanced 
disease
Survival days Treatment 
strategy
437,0 Male ESCC 3 No 23 3
< 94 Women ESCC 2 Yes 207 2
<31 Male ESCC 1 No 98 3
27,3 Male ESCC 2 Yes 30 4
<17 Women ESCC 1 No 1569 2
15,7 Women ESCC 1 No 626 3
6,6 Male ESCC 0 No **1343 3
5,3 Women MEC 0 No 650 2
3,3 Male ESCC 0 No 1028 2
2,1 Male AC 0 Yes 1870 4
0,6 Male AC nd No 1854 3
0,6 Women AC 3 No 73 4
0,5 Male ESCC 0 No 492 1
0,2 Male AC 0 No 934 2
0,2 Women AC 1 Yes 168 4
0,1 Male ESCC 3 Yes 6 4BMC Cancer 2006, 6:94 http://www.biomedcentral.com/1471-2407/6/94
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cinomas and tonsil cancer. However, a subgroup of
younger, no smoking tonsil cancer patients with HPV pos-
itive tumors indicates a different etiology for tonsil cancer
besides excess smoking and alcohol consumption [6,13].
In the present study, we were unable to address this
because of few observations in the HPV positive group of
patients.
Viral load has previously been investigated in esophageal
carcinoma tumors with PCR technology [18]. Si et al
report up to 157 genomes/human genome equivalents for
HPV 16 in esophageal carcinoma tumors. By contrast,
HPV 18 was only detected in 6 of 319 cases and a median
HPV viral load of 4.9 genomes/human genome equiva-
lents [18]. Weston et al differentiates the HPV types as
high risk and low risk HPV types and report one of 40
cases with a high risk HPV type [19]. In our study, HPV 16
was detected in 16% of the cases, but none of the other
viral types were found.
The prognostic value of HPV status has previously been
investigated in patients with esophageal carcinoma
[20,21]. Furihata et al report that HPV positive patients
have worse survival than HPV negative patients with an
over-expression of p53 in esophageal carcinoma patients.
They conclude that each of the two factors, HPV infection
and p53 over-expression, indicate poor prognosis [21].
Hippelainen et al examined 61 patients with esophageal
carcinomas and report that HPV were involved in 11% of
the tumors but without prognostic value for presence of
HPV [20]. In the present study, HPV 16 infection was not
associated with higher survival rate. However, for patients
having a HPV 16 viral load > 1.0 viral genome per cell, an
indication of higher survival rate was found in compari-
son with patients having a HPV 16 viral load < 1.0 viral
genome per cell (Figure 2).
Lindel et al report HPV status as a prognostic parameter
for radiotherapy response in cervical carcinoma patients
[22]. Further, Harima et al report that HPV negative
patients have poorer outcome than HPV positive patients
after radiotherapy and concludes that HPV status might be
useful to optimize for treatment options [7].
We investigated the HPV positive patients in relation to
treatment. HPV positive patients receiving radiation treat-
ment indicated a trend towards better survival, although
this was not statistically significant (p = 0.16). Integration
of HPV result in higher expression of the oncoproteins E6/
E7, thereby abrogating the p53 and Rb protein functions,
promoting genomic rearrangements [23] and develop-
ment of cervical carcinoma [24]. Rearranged DNA is theo-
retically more sensitive to radiation, providing an
explanation for the indication of a higher survival rate for
patients with HPV positive tumors. However, our results
should be interpreted with caution due to the small
number of cases investigated. For patients receiving chem-
otherapeutic treatment (mainly neoadjuvant cisplatin-
based chemotherapeutic combinations), we see a ten-
dency towards better survival (p = 0.22). In vitro studies
report that cisplatin sensitivity is increased in HPV 16
transfected ovarian cancer cells [25], in accordance with
results from the present study.
In conclusion, we employed a sensitive real-time PCR
assay for analysis of paraffin-embedded tissue from
patients with esophageal carcinoma. Among the 100
patients investigated, HPV 16 was present in 16% of the
patients. Given the limited sample size, the results of this
pilot study should be interpreted with caution. However,
the results indicate a positive association of HPV 16 viral
load with survival and motivate further studies of the role
of HPV 16 viral load in patients with esophageal carci-
noma.
Conclusion
Only HPV 16 was detected among the patients. HPV 16 in
esophageal carcinoma patients did not influence survival
or improve therapy response. However, given the size of
the study there is a need to examine a larger cohort in
order to understand in more detail the effect of high risk
HPV types in esophageal carcinoma.
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Survival analysis including sixteen HPV 16 positive cases with  respect to their HPV 16 viral load, divided into HPV 16 load  <1.0 genomes/human genome equivalents or HPV 16 load  >1.0 genomes/human genome equivalents Figure 2
Survival analysis including sixteen HPV 16 positive cases with 
respect to their HPV 16 viral load, divided into HPV 16 load 
<1.0 genomes/human genome equivalents or HPV 16 load 
>1.0 genomes/human genome equivalents.
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